

# Eva Gonzalez-Suarez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7592300/publications.pdf>

Version: 2024-02-01

55  
papers

4,265  
citations

147801

31  
h-index

155660

55  
g-index

62  
all docs

62  
docs citations

62  
times ranked

7471  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017, 17, 254-268.	28.4	527
2	RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. <i>Nature</i> , 2010, 468, 103-107.	27.8	510
3	Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. <i>EMBO Journal</i> , 2001, 20, 2619-2630.	7.8	325
4	Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. <i>Nature Genetics</i> , 2000, 26, 114-117.	21.4	319
5	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 547-573.	5.9	189
6	RANK Induces Epithelial-Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis. <i>Cancer Research</i> , 2012, 72, 2879-2888.	0.9	172
7	<i>BRCA1</i> CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)-Ribose Polymerase Inhibitors. <i>Journal of Clinical Oncology</i> , 2010, 28, e563-e564.	1.6	152
8	RANKL/RANK control <i>Brca1</i> mutation-driven mammary tumors. <i>Cell Research</i> , 2016, 26, 761-774.	12.0	128
9	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. <i>Nature Genetics</i> , 2021, 53, 86-99.	21.4	118
10	BTNL2, a Butyrophilin/B7-Like Molecule, Is a Negative Costimulatory Molecule Modulated in Intestinal Inflammation. <i>Journal of Immunology</i> , 2007, 178, 1523-1533.	0.8	116
11	RANK Overexpression in Transgenic Mice with Mouse Mammary Tumor Virus Promoter-Controlled RANK Increases Proliferation and Impairs Alveolar Differentiation in the Mammary Epithelia and Disrupts Lumen Formation in Cultured Epithelial Acini. <i>Molecular and Cellular Biology</i> , 2007, 27, 1442-1454.	2.3	109
12	Antagonistic effects of telomerase on cancer and aging in K5-mTert transgenic mice. <i>Oncogene</i> , 2005, 24, 2256-2270.	5.9	95
13	Cooperation between p53 Mutation and High Telomerase Transgenic Expression in Spontaneous Cancer Development. <i>Molecular and Cellular Biology</i> , 2002, 22, 7291-7301.	2.3	85
14	Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. <i>Cancer Treatment Reviews</i> , 2019, 76, 57-67.	7.7	85
15	Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability. <i>Journal of Cell Biology</i> , 2001, 154, 49-60.	5.2	83
16	Linkage of DNA Methylation Quantitative Trait Loci to Human Cancer Risk. <i>Cell Reports</i> , 2014, 7, 331-338.	6.4	76
17	Targeting p38 $\beta$ Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells. <i>Cancer Cell</i> , 2018, 33, 1094-1110.e8.	16.8	70
18	A Comprehensive DNA Methylation Profile of Epithelial-to-Mesenchymal Transition. <i>Cancer Research</i> , 2014, 74, 5608-5619.	0.9	69

#	ARTICLE	IF	CITATIONS
19	Expression of mTert in primary murine cells links the growth-promoting effects of telomerase to transforming growth factor- $\beta$ signaling. <i>Oncogene</i> , 2006, 25, 4310-4319.	5.9	64
20	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. <i>Stem Cell Reports</i> , 2017, 8, 1392-1407.	4.8	62
21	Targeting RANKL in metastasis. <i>BoneKEy Reports</i> , 2014, 3, 519.	2.7	60
22	Identification of NOG as a Specific Breast Cancer Bone Metastasis-supporting Gene. <i>Journal of Biological Chemistry</i> , 2012, 287, 21346-21355.	3.4	56
23	Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer. <i>Oncogene</i> , 2019, 38, 7106-7112.	5.9	48
24	Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs. <i>PLoS ONE</i> , 2015, 10, e0131241.	2.5	48
25	RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation. <i>Cancer Research</i> , 2016, 76, 5857-5869.	0.9	47
26	<scp>RANK</scp> as a therapeutic target in cancer. <i>FEBS Journal</i> , 2016, 283, 2018-2033.	4.7	47
27	Progeny of Lgr5-expressing hair follicle stem cell contributes to papillomavirus-induced tumor development in epidermis. <i>Oncogene</i> , 2013, 32, 3732-3743.	5.9	46
28	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	12.8	46
29	Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. <i>Stem Cells</i> , 2013, 31, 1954-1965.	3.2	40
30	FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies. <i>Oncotarget</i> , 2015, 6, 44254-44273.	1.8	35
31	APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer. <i>Carcinogenesis</i> , 2015, 36, 574-584.	2.8	34
32	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. <i>Oncogene</i> , 2017, 36, 2737-2749.	5.9	34
33	RANKL inhibition decreases the incidence of mammary adenocarcinomas in wild type (WT) and MMTV-RANK transgenic mice.. <i>Cancer Research</i> , 2009, 69, 4167.	0.9	34
34	RANKL inhibition: a promising novel strategy for breast cancer treatment. <i>Clinical and Translational Oncology</i> , 2011, 13, 222-228.	2.4	26
35	Rankl Impairs Lactogenic Differentiation Through Inhibition of the Prolactin/Stat5 Pathway at Midgestation. <i>Stem Cells</i> , 2016, 34, 1027-1039.	3.2	26
36	PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma. <i>Oncogene</i> , 2019, 38, 5021-5037.	5.9	26

#	ARTICLE	IF	CITATIONS
37	Telomerase inhibition in RenCa, a murine tumor cell line with short telomeres, by overexpression of a dominant negative mTERT mutant, reveals fundamental differences in telomerase regulation between human and murine cells. <i>Cancer Research</i> , 2001, 61, 5580-6.	0.9	26
38	Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer. <i>Oncotarget</i> , 2017, 8, 51621-51629.	1.8	24
39	Cancer Stem-like Cells Act via Distinct Signaling Pathways in Promoting Late Stages of Malignant Progression. <i>Cancer Research</i> , 2016, 76, 1245-1259.	0.9	21
40	RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness. <i>Developmental Cell</i> , 2021, 56, 1727-1741.e7.	7.0	21
41	The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. <i>Molecular Cancer Research</i> , 2019, 17, 2063-2076.	3.4	20
42	Chromosome 12p Amplification in Triple-Negative/ <i>BRCA1</i> -Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. <i>Cancer Research</i> , 2019, 79, 4258-4270.	0.9	17
43	Telomere dysfunction results in enhanced organismal sensitivity to the alkylating agent N-methyl-N-nitrosourea. <i>Cancer Research</i> , 2003, 63, 7047-50.	0.9	17
44	Lymphangioliomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness. <i>PLoS ONE</i> , 2015, 10, e0132546.	2.5	15
45	FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1491-1504.	7.0	13
46	Evidence for a link between TNFRSF11A and risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 947-954.	2.5	12
47	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 42.	5.0	11
48	Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1338208.	0.7	10
49	RANKL inhibitors for osteosarcoma treatment: hope and caution. <i>Annals of Translational Medicine</i> , 2016, 4, 534-534.	1.7	10
50	Cancer network activity associated with therapeutic response and synergism. <i>Genome Medicine</i> , 2016, 8, 88.	8.2	7
51	Inhibition of RANK signaling as a potential immunotherapy in breast cancer. <i>Oncolmmunology</i> , 2021, 10, 1923156.	4.6	3
52	494 POSTER MMTV-RANK transgenic mice show increased mammary epithelial proliferation and impaired alveolar differentiation during pregnancy and a higher incidence of chemically induced mammary tumors. <i>European Journal of Cancer</i> , Supplement, 2006, 4, 150-151.	2.2	0
53	111: RANK pathway as a new therapeutic target in primary breast cancer. <i>European Journal of Cancer</i> , 2014, 50, S25.	2.8	0
54	Abstract 3280: Generation of orthotopic mouse models of breast cancer. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract S4-8: Promoter CpG Methylation ofBRCA1Predicts Sensitivity to PARP Inhibitors in Breast Cancer. , 2010, , .		0